Natalie Beyeler, DO
Internal Medicine · Palmer, AKNPI 1104885268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 25.3% of the total. Reporting peaked in 2020 at $731 and has fallen 77.4% since, to $165 in 2025.
Across 126 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$631
- AbbVie$341
- Merck$175
- Lilly USA, LLC$166
- GSK$165
- Vanda Pharmaceuticals Inc.$131
- plus $889 from 21 others
What the payments were for
- Food & beverage$2,42697%
- Education$713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $631 |
| AbbVie | 17 | $341 |
| Merck | 10 | $175 |
| Lilly USA, LLC | 10 | $166 |
| GSK | 9 | $165 |
| Vanda Pharmaceuticals Inc. | 7 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $129 |
| Pfizer | 5 | $123 |
| Radius Health, Inc. | 4 | $76 |
| Astellas Pharma US Inc | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Biogen | 3 | $49 |
| Amgen | 2 | $45 |
| Novo Nordisk | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $42 |
| Exact Sciences | 2 | $39 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Digestive Care, Inc. | 1 | $25 |
| CSL Behring | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
How this compares
$2,496 in reported general payments places this provider in the 85th percentile of 124 internal medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $149,183 |
| OzempicSemaglutide | 42 | $83,116 |
| CreonLipase/Protease/Amylase | 28 | $82,954 |
| MounjaroTirzepatide | 33 | $42,947 |
| FarxigaDapagliflozin Propanediol | 26 | $41,618 |
| Dexlansoprazole DrDexlansoprazole | 75 | $38,277 |
| EliquisApixaban | 42 | $37,618 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $35,037 |
| Sucralfate | 110 | $34,613 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $34,047 |
| Icosapent Ethyl | 58 | $30,092 |
| MyrbetriqMirabegron | 22 | $27,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $26,884 |
| XareltoRivaroxaban | 22 | $25,340 |
| SynthroidLevothyroxine Sodium | 200 | $21,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $17 | $149,18314 claims |
| AbbVieCreon, Synthroid | $341 | $103,974228 claims |
| Novo NordiskOzempic, Rybelsus | $45 | $103,53553 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $631 | $75,66454 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $165 | $69,30978 claims |
| PfizerEliquis, Premarin | $123 | $48,22062 claims |
| Lilly USA, LLCMounjaro | $166 | $42,94733 claims |
| Boehringer IngelheimCombivent Respimat, Tradjenta | $23 | $36,58445 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $27,36622 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $24 | $20,48022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 internal medicine providers in Alaska.
Other internal medicine in Palmer
- Martin CookPalmer$1K
- Marcus ThiemannPalmer$1K
- Srikanth MalladiPalmer$179
- David BarnesWasilla$11K
- Loretta LeeAnchorage$8K
- Andrew CapGlennallen$7K
- Susan HeverlingAnchorage$6K
- Laurie MontanoAnchorage$6K
- Michele O FallonAnchorage$6K
- John BostonWasilla$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.